Lurasidone-Associated Cardiac Adverse Effects
Lurasidone can cause cardiac adverse effects that may present clinically as chest pain, including angina pectoris (listed as an infrequent cardiac disorder) and tachycardia (listed as a frequent cardiac disorder). [1]
Chest Pain Evaluation Versus Drug Causality
Chest pain requires immediate medical evaluation to assess for acute coronary syndrome or other life-threatening causes regardless of whether an association with lurasidone is suspected. [1]
Evidence for Chest-Pain–Compatible Reactions
Lurasidone labeling reports cardiac disorders of clinical importance that overlap with chest-pain presentations:
- Angina pectoris is listed under cardiac disorders (infrequent). [1]
- Tachycardia is listed under cardiac disorders (frequent). [1]
QT Prolongation Considerations
Lurasidone has been studied for effects on QTc, with QTc increases measured in a dedicated thorough QT study and no report of post-baseline QT prolongation exceeding 500 msec in short-term placebo-controlled studies in schizophrenia and bipolar depression. [1]
Discontinuation Pending Cardiac Evaluation
Automatic discontinuation of lurasidone solely due to chest pain is not specified as a labeling requirement. [1]
Stopping lurasidone without clinician guidance is discouraged in patient-facing information. [2]
Practical Management Approach
- If chest pain is present, urgent cardiac assessment is indicated before determining whether lurasidone should be continued. [1]
- Continuation versus temporary interruption should be directed by the prescriber after cardiac evaluation and consideration of other contributing risk factors and interacting medications. [1]
- Lurasidone is not recommended to be stopped without clinician discussion. [2]
Safety Data Points Relevant to Decision-Making
In addition to angina pectoris and tachycardia, lurasidone labeling includes other cardiac disorders that may influence cardiac risk assessment (for example, AV block first degree and bradycardia). [1]